David A. Siegel G1 Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.2 - $4.98 $61,600 - $139,440	28,000 Added 15.24%	211,700 $482,000
Q1 2024 May 15, 2024	BUY	$2.1 - $4.83 $106,890 - $245,847	50,900 Added 38.33%	183,700 $793,000
Q4 2023 Feb 14, 2024	SELL	$1.12 - $3.73 $94,752 - $315,558	-84,600 Reduced 38.91%	132,800 $405,000
Q3 2023 Nov 14, 2023	BUY	$1.22 - $2.67 $163,480 - $357,780	134,000 Added 160.67%	217,400 $313,000
Q2 2023 Aug 14, 2023	SELL	$2.46 - $3.14 $469,368 - $599,112	-190,800 Reduced 69.58%	83,400 $207,000
Q1 2023 May 15, 2023	SELL	$2.57 - $8.16 $117,191 - $372,096	-45,600 Reduced 14.26%	274,200 $734,000
Q4 2022 Feb 14, 2023	BUY	$5.19 - $13.5 $1.52 Million - $3.96 Million	293,400 Added 1111.36%	319,800 $1.74 Million
Q3 2022 Nov 14, 2022	SELL	$5.17 - $16.99 $28,952 - $95,143	-5,600 Reduced 17.5%	26,400 $330,000
Q2 2022 Aug 15, 2022	SELL	$4.04 - $8.51 $202,808 - $427,202	-50,200 Reduced 61.07%	32,000 $158,000
Q1 2022 May 16, 2022	SELL	$7.6 - $11.02 $1.12 Million - $1.62 Million	-146,716 Reduced 64.09%	82,200 $625,000
Q4 2021 Feb 14, 2022	SELL	$10.16 - $16.17 $1.12 Million - $1.78 Million	-109,800 Reduced 32.42%	228,916 $2.34 Million
Q3 2021 Nov 15, 2021	SELL	$13.16 - $22.47 $2.69 Million - $4.59 Million	-204,200 Reduced 37.61%	338,716 $4.55 Million
Q2 2021 Aug 16, 2021	SELL	$19.57 - $26.32 $1.41 Million - $1.9 Million	-72,000 Reduced 11.71%	542,916 $11.9 Million
Q1 2021 May 17, 2021	BUY	$17.58 - $32.59 $2.38 Million - $4.4 Million	135,100 Added 28.16%	614,916 $14.8 Million
Q4 2020 Feb 16, 2021	BUY	$10.99 - $20.4 $4.07 Million - $7.56 Million	370,400 Added 338.52%	479,816 $8.63 Million
Q3 2020 Nov 16, 2020	SELL	$11.55 - $23.75 $62,370 - $128,250	-5,400 Reduced 4.7%	109,416 $1.26 Million
Q2 2020 Aug 14, 2020	BUY	$9.57 - $24.37 $78,474 - $199,834	8,200 Added 7.69%	114,816 $2.79 Million
Q1 2020 May 15, 2020	BUY	$9.07 - $26.32 $429,918 - $1.25 Million	47,400 Added 80.05%	106,616 $1.18 Million
Q4 2019 Feb 14, 2020	BUY	$20.54 - $31.0 $844,522 - $1.27 Million	41,116 Added 227.16%	59,216 $1.57 Million
Q3 2019 Nov 14, 2019	SELL	$22.78 - $40.58 $236,912 - $422,032	-10,400 Reduced 36.49%	18,100 $412,000
Q2 2019 Aug 14, 2019	SELL	$16.03 - $31.1 $57,708 - $111,960	-3,600 Reduced 11.21%	28,500 $874,000
Q1 2019 May 15, 2019	BUY	$14.4 - $21.45 $46,080 - $68,640	3,200 Added 11.07%	32,100 $533,000
Q4 2018 Feb 14, 2019	BUY	$16.51 - $51.33 $31,369 - $97,527	1,900 Added 7.04%	28,900 $553,000
Q3 2018 Nov 14, 2018	BUY	$43.15 - $67.97 $552,320 - $870,016	12,800 Added 90.14%	27,000 $1.41 Million
Q2 2018 Aug 14, 2018	BUY	$35.06 - $51.17 $497,852 - $726,614	14,200 New	14,200 $617,000

Others Institutions Holding GTHX

# of Institutions

Shares Held

3.55M

Call Options Held

11.7K

Put Options Held

View Full List

About G1 Therapeutics, Inc.

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $306M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

More about GTHX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account